Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.40 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093683 | 0.88 | GRIN2B (0.42) | GRIN2BNAMPTCCR2ABL1DRD2 | |
| SCHEMBL6097322 | 0.83 | GRIN2B (0.41) | EPHX2GRIN2BNAMPTCCR2DRD2 | |
| SCHEMBL6094074 | 0.83 | KCNA5 (0.47) | GRIN2BNAMPTCCR2ABL1 | |
| SCHEMBL6094104 | 0.83 | GRIN2B (0.58) | GRIN2BNAMPT | |
| SCHEMBL6095508 | 0.78 | HRH2 (0.41) | EPHX2DRD2DRD3FAAH | |
| SCHEMBL6094937 | 0.78 | GRIN2B (0.45) | GRIN2BNAMPTCCR2ABL1 | |
| SCHEMBL6095439 | 0.77 | GRIN2B (0.40) | GRIN2BNAMPTABL1 | |
| SCHEMBL6095400 | 0.77 | HTR7 (0.42) | EPHX2 | |
| SCHEMBL6092565 | 0.77 | GRIN2B (0.45) | GRIN2BNAMPTCCR2ABL1FAAH | |
| SCHEMBL6093925 | 0.77 | HRH2 (0.41) | EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | EPHX2 3084/4885GRIN2B 921/4885NAMPT 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.